Home
CancerNetwork

CancerNetwork Market Share Analysis for May 2026

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

Health > Health - Other

Domaincancernetwork.com

Year Founded--

Employees51 - 200

Annual Revenue$2M - $5M

CancerNetwork

CancerNetwork (including company regionals)

cancernetwork.com

See more website traffic and engagement information

CancerNetwork Revenue up to May 2026 is 2M - 5M

revenue generated by CancerNetwork top domains

CancerNetwork top domains revenue over 3 years

Revenue for CancerNetwork top domains

cancernetwork.com2M - 5M

See more with Sales Intelligence

Total visits to CancerNetwork's top domains

Understand CancerNetwork market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cancernetwork.com136.1K

See more with Sales Intelligence

Avg. visit duration in CancerNetwork's top domains

Analyze CancerNetwork engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

cancernetwork.com00:00:50

See more with Sales Intelligence

Avg. pageviews on CancerNetwork's top domains

See how CancerNetwork keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cancernetwork.com1.65

See more with Sales Intelligence

CancerNetwork top competitors by domain

Top similar sites in May 2026, ranked by their affinity

onclive.comCompany NameOncLiveEmployees51 - 200HQUnited States, New Jersey, CranburyAnnual revenue$5M - $10MTotal visits183.5KHealth > Health Conditions and Concerns

Top technologies used by CancerNetwork

These are the website technologies, by industry, used by CancerNetwork top domains

Advertising (21)

Google Adsense

Conversion & Analytics (12)

Google Analytics

Payment & Currencies (6)

Euro

Social (6)

Instagram

More Technologies

11

See all

News & Signals from CancerNetwork

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCancernetwork attends event European Hematology Association (EHA) 2026 Congress.In an interview with CancerNetwork(R) at the European Hematology Association (EHA) 2026 Congress, Emmanuel Bachy, MD, PhD, presented data from the phase 1b/2 CO41942 study (NCT04246086) evaluating the efficacy and safety profile of subcutaneous mosunetuzumab (Lunsumio VELO) for the treatment of patients with previously untreated follicular lymphoma meeting high tumor burden criteria.

NewsCancernetwork attends event 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.In an interview with CancerNetwork(R) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Sonali Smith, MD, highlighted a key takeaway from the phase 3 frontMIND trial (NCT04824092), which was the first to examine the efficacy of a regimen consisting of rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL).

NewsCancernetwork is developing The Bispecifics Network.CancerNetwork, AJMC, and Pharmacy Times are producing The Bispecifics Network, where Ralph V. Boccia, MD, FACP, breaks down the importance of this initiative.